

Original Paper

# Activation of M<sub>3</sub> Muscarinic Acetylcholine Receptors Delayed Cardiac Aging by Inhibiting the Caspase-1/IL-1 $\beta$ Signaling Pathway

Shu Wang<sup>a</sup> Yanan Jiang<sup>b,c</sup> Jingling Chen<sup>a</sup> Changliang Dai<sup>a</sup> Dandan Liu<sup>a</sup>  
Wei Pan<sup>a</sup> Lijuan Wang<sup>b</sup> Moyondafoluwa Blessing Fasae<sup>b</sup> Lihua Sun<sup>b</sup>  
Lanfeng Wang<sup>a</sup> Yan Liu<sup>b,d</sup>

<sup>a</sup>Department of Cardiology, the First Affiliated Hospital of Harbin Medical University, Harbin,

<sup>b</sup>Department of Pharmacology (State-Province Key Laboratories of Biomedicine-Pharmaceutics of China, Key Laboratory of Cardiovascular Medicine Research, Ministry of Education), College of Pharmacy, Harbin Medical University, Harbin, <sup>c</sup>North China Translational Medicine Research and Cooperation Center, Institute of Medical Sciences of Heilongjiang Province, Harbin, <sup>d</sup>Department of Pharmacology, College of Pharmacy, Hainan Medical University, Haikou, China

## Key Words

M<sub>3</sub> muscarinic acetylcholine receptor • Cardiac aging • Caspase-1 • IL-1 $\beta$

## Abstract

**Background/Aims:** Because the prevalence of age-related cardiac impairment increases as the human lifespan increases, it is important to combat the effects of aging. Recently, the cardiac M<sub>3</sub> muscarinic acetylcholine receptor (M<sub>3</sub>-mAChR) has been demonstrated to play important roles in cardiac development and in the pathogenesis of cardiac diseases. However, the role of M<sub>3</sub>-mAChR in aging remains largely unknown. Therefore, the aim of this study was to investigate the involvement of M<sub>3</sub>-mAChR in the progression of cardiac aging.

**Methods:** We established a cardiac aging model in mice through subcutaneous injection with D-galactose at a dose of 100 mg/kg/day for 6 weeks. D-galactose was also used to induce aging in primary cultured neonatal mouse cardiomyocytes. The myocardium from mice was stained with hematoxylin and eosin for histological analysis. The protein expression levels of p53 and p21 were determined using western blotting. The mRNA and protein expression levels of M<sub>3</sub>-mAChR, caspase-1, and interleukin (IL)-1 $\beta$  were determined using real-time PCR, immunohistochemical staining, and western blotting. **Results:** The expression of M<sub>3</sub>-mAChR was down-regulated in the myocardium from aged mice and D-galactose-treated mice, while the expression levels of caspase-1 and its downstream molecule IL-1 $\beta$  were significantly increased. The M<sub>3</sub>-mAChR agonist choline reduced the increase in caspase-1 in cardiomyocytes

S. Wang and Y. Jiang contributed equally to this work.

Lanfeng Wang  
and Yan Liu

Department of Cardiology, The First Affiliated Hospital of Harbin Medical University  
Harbin (China)  
E-Mail lanfengwang@hotmail.com; liuyan\_gyp@163.com

induced by D-galactose, which was reversed by the M<sub>3</sub>-mAChR antagonist 4-DAMP. Moreover, 4-DAMP promoted D-galactose-induced cardiomyocyte aging, which was attenuated by a caspase-1 inhibitor. **Conclusion:** Activation of M<sub>3</sub>-mAChR delayed cardiac aging by inhibiting the caspase-1/IL-1 $\beta$  signaling pathway.

© 2018 The Author(s)  
Published by S. Karger AG, Basel

## Introduction

According to the World Health Organization, the world's population aged 60 years and older is expected to total 2 billion by 2050, up from 841 million today [1]. Associated with a progressive loss of physiological integrity, aging is one of the greatest known risk factors for most human diseases [2]. Unfortunately, the exact mechanisms underlying the process of aging are still unclear. Recent studies have indicated that inflammation plays an increasingly important role in the rate of aging and age-related diseases [3, 4].

The aging process is accompanied by inflammatory activation and cytokine release, which are responsible for age-related cardiac dysfunction [5]. In particular, NOD-like receptor 3 (NLRP3), a key component of the inflammasome, is an important regulator of age-related inflammation [6]. Also, the NLRP3 inflammasome promotes the activation of caspase-1, which cleaves the inactive precursors of interleukin (IL)-1 $\beta$  and IL-18 and stimulates their secretion [7]. These cytokines provoke inflammatory responses and accelerate the process of aging [8].

The autonomic nervous system regulates heart function through transmitters and modulators binding to cell surface receptors. Among these cell surface receptors, the cardiac M<sub>3</sub> muscarinic acetylcholine receptor (M<sub>3</sub>-mAChR) plays important roles in the maintenance of cardiac function and the generation and progression of cardiac diseases [9-11]. Through the activation of a delayed rectifying K<sup>+</sup> current I<sub>KM3</sub> to modulate cardiac membrane repolarization, M<sub>3</sub>-mAChR exerts anti-arrhythmia effects [12, 13]. M<sub>3</sub>-mAChR enhances endogenous antioxidant capacity and decreases intracellular Ca<sup>2+</sup> overload. The up-regulation of M<sub>3</sub>-mAChR was also found to alleviate angiotensin II-induced cardiac hypertrophy [14, 15]. These findings indicate that M<sub>3</sub>-mAChR contributes to the protection against cardiac injury.

The pathophysiological role of cardiac M<sub>3</sub>-mAChR is currently under investigation. In a preliminary experiment, we found that M<sub>3</sub>-mAChR expression was down-regulated in the myocardium of aged mice. Therefore, in the present study, we investigated the role of M<sub>3</sub>-mAChR in the progression of cardiac aging and explored the underlying mechanisms.

## Materials and Methods

### *Cardiac aging mouse model*

Mice were injected subcutaneously with D-galactose at a dose of 100 mg/kg/day or the same volume of solvent for 6 weeks. After treatment, mice were sacrificed and the myocardium excised and used for experiments. The experimental protocols were approved by the Ethics Committee of Harbin Medical University, P. R. China. Use of animals conformed to the US National Institutes of Health (NIH) guide for the care and use of laboratory animals (NIH Publication No. 85-23, revised 1996).

### *Hematoxylin and eosin staining*

Mouse myocardial samples were fixed in 4% paraformaldehyde followed by dehydration. The processed samples were embedded in paraffin and cut into 5- $\mu$ m thick sections using tissue-processing equipment. The sections were deparaffinized and stained with hematoxylin and eosin (HE) for histological analysis.

### *Immunohistochemical staining*

Myocardial samples were fixed with 4% buffered paraformaldehyde, dehydrated, and embedded in paraffin. Sections (5 μm) were deparaffinized, rehydrated, and rinsed in distilled water. Antigen unmasking was carried out by microwave heating in citrate buffer for 20 min. Sections were immunostained with primary antibody against M<sub>3</sub>-mAChR (Alomone, Jerusalem, Israel), caspase-1 (Cell Signaling Technology, Danvers, MA), or IL-1β (Cell Signaling Technology) at 4°C overnight. After incubation with the secondary antibody, the sections were stained with diaminobenzidine.

### *Isolation and culture of neonatal mouse cardiomyocytes*

Neonatal mice (1–3 days old) were sterilized by 75% ethanol solution and then sacrificed. Hearts were extracted and transferred immediately into a Petri dish containing cold Dulbecco's modified Eagle medium (DMEM) (HyClone Technologies, Logan, UT). The ventricles were washed and minced into small pieces. The cells were dissociated at 37°C with trypsin-EDTA solution (Beyotime Institute of Biotechnology, Jiangsu, China). Following dissociation, cells were added to an equal volume of DMEM containing 10% fetal bovine serum (Biological Industries, Kibbutz Beit Haemek, Israel) and kept at 4°C. After final collection, the resulting mixture was filtered and centrifuged for 3 min at 1500 rpm to obtain a pellet of cells. The cells were resuspended in culture medium and incubated for 1.5 h under a water-saturated atmosphere of 5% CO<sub>2</sub>-95% air to allow the attachment of non-cardiomyocytes. The suspended cells were then collected, plated onto a new culture plate, and incubated under the same conditions as described above [16].

### *Real-time PCR*

Total RNA was extracted from cells or tissues using Trizol reagent (Roche, Indianapolis, IN). Then, 500 ng RNA was reverse transcribed to cDNA using Reverse Transcription Master Kit (Toyobo, Osaka, Japan) according to the manufacturer's instructions. Real-time PCR was performed using an ABI 7500 fast system (Applied Biosystems, Carlsbad, CA) with SYBR Green I (Toyobo). The sequences of the primer pairs are as follows. M<sub>3</sub>-mAChR: forward 5'-GTCTGGCTTGGGTCATCTCCT-3', reverse 5'-GCTGCTGCTGGTCTTGGCT-3'; caspase-1: forward 5'-ACACGTCTTGCCCTCATTATCT-3', reverse 5'-ATAACCTTGGGCTTGTCTTTCA-3'; IL-1β: forward 5'-CCCTGCAGCTGGAGAGTGTGG-3', reverse 5'-TGTGCTCTGCTTGAGAGGTGCT-3'; and GAPDH: forward 5'-ATCACTGCCACCCAGAAGAC3', reverse 5'-TTTCTAGACGGCAGGTCAGG-3'. GAPDH served as an internal control. The relative quantification of gene expression was determined using the 2<sup>-ΔΔCT</sup> method.

### *Western blotting*

Total protein was extracted from cells or tissues. The suspension was subjected to 10% acrylamide gel electrophoresis and then electrotransferred onto a nitrocellulose filter. After blocking with 5% (w/v) non-fat milk dissolved in phosphate-buffered saline for 2 h, membranes were incubated at 4°C overnight with primary antibodies against p53 (Cell Signaling Technology), p21 (Cell Signaling Technology), M<sub>3</sub>-mAChR (Alomone, Jerusalem, Israel), caspase-1 (Cell Signaling Technology), IL-1β (Cell Signaling Technology), and GAPDH (ZSGB-BIO, Beijing, China), followed by incubation with horseradish peroxidase-labeled goat anti-mouse IgG or anti-rabbit IgG (1:1000) (ZSGB-BIO) for 1 h. The intensities of immunoblot bands were quantified using Quantity One software (Bio-Rad Laboratories, Hercules, CA).

### *Statistical analysis*

Data were analyzed with SPSS 13.0 software (SPSS Inc., Chicago, IL). Statistical comparisons between two groups were performed using Student's *t*-test. Statistical comparisons among multiple groups were performed using analysis of variance. A two-tailed *P*-value < 0.05 was considered statistically significant. Data are presented as mean and standard error of the mean.

## Results

### *Expression of M<sub>3</sub>-mAChR was down-regulated in the myocardium from aged mice*


Several studies have demonstrated that the expression of M<sub>3</sub>-mAChR is increased in patients with atrial fibrillation, atrial dilation, ventricular myocardial ischemia, and cardiac hypertrophy [13, 14, 17]. Whether the expression of M<sub>3</sub>-mAChR is changed in the process

of aging has not been determined. Therefore, we compared aged mice (18–20 months old) with young mice (8–12 weeks old). HE staining showed the characteristics of the heart from young and aged mice (Fig. 1 A). The expression levels of p53 and p21, markers of aging, were significantly upregulated in the myocardium of aged mice (Fig. 1 B & C). Immunohistochemical staining, real-time PCR, and western blotting confirmed the down-regulation of M<sub>3</sub>-mAChR in the myocardium from aged mice compared with young mice at both mRNA and protein levels (Fig. 1 D–F).


*Expression levels of caspase-1 and IL-1 $\beta$  were up-regulated in the myocardium from aged mice*

The caspase-1/IL-1 $\beta$  pathway is an essential signaling pathway for inflammation. It has been reported that the expression of caspase-1 was significantly increased in the process of


**Fig. 1.** Expression of M<sub>3</sub>-mAChR was down-regulated in the myocardium from aged mice. A. Histopathological characteristics of the heart from young and aged mice. B. Protein expression of p53 in young and aged mice. C. Protein expression of p21 in young and aged mice. D. Immunohistochemical staining of M<sub>3</sub>-mAChR in young and aged mice. E. mRNA expression of M<sub>3</sub>-mAChR in young and aged mice. F. Protein expression of M<sub>3</sub>-mAChR in young and aged mice. GAPDH served as an internal control. \* P<0.05 vs. young group; n = 5.



**Fig. 2.** Expression levels of caspase-1 and IL-1 $\beta$  were up-regulated in the myocardium of aged mice. A. Immunohistochemical staining of caspase-1 in young and aged mice. B. mRNA expression of caspase-1 in young and aged mice. C. Protein expression of caspase-1 in young and aged mice. D. Immunohistochemical staining of IL-1 $\beta$  in young and aged mice. E. mRNA expression of IL-1 $\beta$  in young and aged mice. F. Protein expression of IL-1 $\beta$  in young and aged mice. GAPDH served as an internal control. \* P<0.05 vs. young group; n = 5.



**Fig. 3.** Expression of M<sub>3</sub>-mAChR was down-regulated in the myocardium from D-galactose-treated mice. A. Histopathological characteristics of the heart from control and D-galactose-treated mice. B. Protein expression of p53 in control and D-galactose-treated mice. C. Protein expression of p21 in control and D-galactose-treated mice. D. Immunohistochemical staining of M<sub>3</sub>-mAChR in control and D-galactose-treated mice. E. mRNA expression of M<sub>3</sub>-mAChR in control and D-galactose-treated mice. F. Protein expression of M<sub>3</sub>-mAChR in control and D-galactose-treated mice. GAPDH served as an internal control. \* P<0.05 vs. control group; n = 5.



aging [18]. A significant increase in caspase-1 immunostaining was found in myocardium from aged mice (Fig. 2 A). To further evaluate the expression of caspase-1, real-time PCR and western blotting experiments were performed. The results showed that the mRNA and protein levels of caspase-1 were up-regulated in aged mice relative to young mice (Fig. 2 B & C). Simultaneously, the expression of IL-1 $\beta$  was also up-regulated (Fig. 2 D–F).

#### *Expression of M<sub>3</sub>-mAChR was down-regulated in the myocardium from D-galactose-treated mice*

D-galactose was used to establish a mouse model of cardiac aging. After treatment, mice were sacrificed and the cardiac tissues were harvested for subsequent experiments. HE staining showed the characteristics of the heart from control and D-galactose-treated mice (Fig. 3 A). Expression levels of the aging markers p53 and p21 were significantly up-regulated in the myocardium of D-galactose-treated mice (Fig. 3 B & C). The expression of M<sub>3</sub>-mAChR was also down-regulated in D-galactose-treated mice (Fig. 3 D–F). These findings suggested the involvement of the decreased expression of M<sub>3</sub>-mAChR in the process of cardiac aging.



#### *Expression levels of caspase-1 and IL-1 $\beta$ were up-regulated in the myocardium from D-galactose-treated mice*

Immunohistochemical staining, real-time PCR, and western blotting results showed that the expressions of caspase-1 and IL-1 $\beta$  were up-regulated at both mRNA and protein levels (Fig. 4 A–F). These findings suggested that increased expression of caspase-1 and IL-1 $\beta$  has a role in the process of cardiac aging.

#### *Activation of M<sub>3</sub>-mAChR reversed the effects of D-galactose on Caspase-1 and IL-1 $\beta$ in cardiomyocytes*


As the expression of M<sub>3</sub>-mAChR was down-regulated in aged mice, we considered that M<sub>3</sub>-mAChR may have a role in the process of cardiac aging. Choline chloride was used to activate M<sub>3</sub>-mAChR, whereas 4-DAMP was used to inhibit M<sub>3</sub>-mAChR. Cardiomyocytes were divided into the following four groups: control, D-galactose, D-galactose + choline (M<sub>3</sub>-mAChR agonist), and D-galactose + choline + 4-DAMP (M<sub>3</sub>-mAChR antagonist) groups. D-galactose up-regulated the expression levels of p53 and p21, which were attenuated by choline. However, 4-DAMP reversed the effect of choline (Fig. 5 A & B). The mRNA and protein levels of caspase-1 and IL-1 $\beta$  were evaluated. The increased expression of caspase-1

**Fig. 4.** Expression levels of caspase-1 and IL-1 $\beta$  were up-regulated in the myocardium from D-galactose-treated mice. A. Immunohistochemical staining of caspase-1 in control and D-galactose-treated mice. B. mRNA expression of caspase-1 in control and D-galactose-treated mice. C. Protein expression of caspase-1 in control and D-galactose-treated mice. D. Immunohistochemical staining of IL-1 $\beta$  in control and D-galactose-treated mice. E. mRNA expression of IL-1 $\beta$  in control and D-galactose-treated mice. F. Protein expression of IL-1 $\beta$  in control and D-galactose-treated mice. GAPDH served as an internal control. \* P<0.05 vs. control group; n = 5.



**Fig. 5.** Activation of M<sub>3</sub>-mAChR reversed the effects of D-galactose on Caspase-1 and IL-1 $\beta$  in cardiomyocytes. A. Protein expression of p53 in cardiomyocytes. B. Protein expression of p21 in cardiomyocytes. C. mRNA expression of caspase-1 in cardiomyocytes. D. Protein expression of caspase-1 in cardiomyocytes. E. mRNA expression of IL-1 $\beta$  in cardiomyocytes. F. Protein expression of IL-1 $\beta$  in cardiomyocytes. GAPDH served as an internal control. \* P<0.05 vs. control group; # P<0.05 vs. D-galactose group; & P<0.05 vs. D-galactose + choline group; n = 3.

induced by D-galactose was inhibited by choline, and this was reversed by 4-DAMP (Fig. 5 C & D). The up-regulation of IL-1 $\beta$ , a downstream cytokine of caspase-1, was also effectively reversed by the M<sub>3</sub>-mAChR agonist (Fig. 5 E & F). These results suggest that activation of M<sub>3</sub>-mAChR can inhibit the caspase-1/IL-1 $\beta$  signaling pathway.



**Fig. 6.** Inhibition of M<sub>3</sub>-mAChR promoted D-galactose-induced cardiomyocyte aging through the caspase-1/IL-1β signaling pathway. A. Protein expression of p53 in cardiomyocytes. B. Protein expression of p21 in cardiomyocytes. C. mRNA expression of M<sub>3</sub>-mAChR in cardiomyocytes. D. Protein expression of M<sub>3</sub>-mAChR in cardiomyocytes. E. mRNA expression of caspase-1 in cardiomyocytes. F. Protein expression of caspase-1 in cardiomyocytes. G. mRNA expression of IL-1β in cardiomyocytes. H. Protein expression of IL-1β in cardiomyocytes. GAPDH served as an internal control. \* P<0.05 vs. control group; # P<0.05 vs. D-galactose group; & P<0.05 vs. D-galactose + 4-DAMP group; n = 3.

*Inhibition of M<sub>3</sub>-mAChR promoted D-galactose-induced cardiomyocyte aging through the caspase-1/IL-1β signaling pathway*

To explore the mechanism underlying the role of M<sub>3</sub>-mAChR in cardiomyocyte aging, neonatal mouse cardiomyocytes were divided into four groups: control, D-galactose, D-galactose + 4-DAMP, and D-galactose + 4-DAMP + Ac-YVAD-CMK (caspase-1 inhibitor) groups. The expression levels of p53, p21, caspase-1, and IL-1β were determined. The results showed that 4-DAMP promoted the effect of D-galactose. However, co-administration of D-galactose + 4-DAMP + Ac-YVAD-CMK attenuated the effect of D-galactose and 4-DAMP (Fig. 6). Therefore, inhibition of caspase-1 could reverse the effect of 4-DAMP in D-galactose-induced cardiomyocyte aging. These results suggest that M<sub>3</sub>-mAChR acted at least partially through regulation of the caspase-1/IL-1β signaling pathway.

**Discussion**

As the global population continues to grow older, understanding of aging as a predominant risk factor for all cardiovascular diseases is essential for revealing the molecular pathogenesis of aging. Furthermore, discovering new therapeutic targets is vital in the prevention and treatment of age-related cardiac diseases. The activation of NLRP3 initiates an inflammatory cascade reaction, which occurs in the processes of aging and cardiac injury [19, 20]. During this process, caspase-1 cleaves the precursors, and stimulates the release, of IL-1β and IL-18, which causes an inflammatory reaction and accelerates aging [7]. It has also been reported that the expression of caspase-1 is increased during the process of aging [18, 21]. Moreover, inhibition of caspase-1 protects the heart from acute myocardial ischemic injury and hypertrophy [22].

The aging process is accompanied by a series of changes in the autonomic control of the cardiovascular system. M<sub>3</sub>-mAChR plays an important role in cardiac function. Many recent studies have revealed the relationship between M<sub>3</sub>-mAChR and cardiac diseases, including cardiac ischemia, pathological cardiac hypertrophy, cardiac arrhythmias, and heart failure [23]. M<sub>3</sub>-mAChR was also involved in LPS-induced lung inflammation and fibroblast proliferation by mediating the NF-κB signaling pathway [24, 25]. These findings suggest that the blockade of M<sub>3</sub>-mAChR exerts anti-inflammatory properties.

In this study, we found that the expression of M<sub>3</sub>-mAChR was down-regulated in the myocardium from aged and D-galactose-treated mice, while the expression levels of caspase-1 and IL-1β were significantly up-regulated. Activation of M<sub>3</sub>-mAChR reduced the increased expression of caspase-1 and IL-1β induced by D-galactose in cardiomyocytes. Furthermore, the inhibition of M<sub>3</sub>-mAChR promoted the effect of D-galactose on cardiomyocytes. However, the caspase-1 inhibitor Ac-YVAD-CMK attenuated the effect of D-galactose and 4-DAMP.

To our knowledge, this is the first study that explored the expression, function, and molecular mechanism of M<sub>3</sub>-mAChR in cardiac aging. Overall, our results suggest that down-regulation of M<sub>3</sub>-mAChR occurs during the process of cardiac aging and the activation of M<sub>3</sub>-mAChR delays cardiac aging by inhibiting the caspase-1/IL-1β signaling pathway. Therefore, activation of M<sub>3</sub>-mAChR may be a new strategy to delay aging.

### Acknowledgements

This work was supported by the China Postdoctoral Science Foundation (Grant No. 2013M541413) and National Natural Science Foundation of China (Grant No. 81401151).

### Disclosure Statement

The authors declare no conflict of interests.

### References

- 1 World Health Organization. 10 facts on ageing and health. <http://www.who.int/features/factfiles/ageing/en/>, 2017-05.
- 2 Dillin A, Gottschling DE, Nystrom T: The good and the bad of being connected: the integrons of aging. *Curr Opin Cell Biol* 2014;26:107-112.
- 3 Chuang SY, Lin CH, Fang JY: Natural compounds and aging: between autophagy and inflammasome. *Biomed Res Int* 2014;2014:297293.
- 4 Xia S, Zhang X, Zheng S, Khanabdali R, Kalionis B, Wu J, Wan W, Tai X: An Update on Inflamm-Aging: Mechanisms, Prevention, and Treatment. *J Immunol Res* 2016;2016:8426874.
- 5 Machi JF, Dias Dda S, Freitas SC, de Moraes OA, da Silva MB, Cruz PL, Mostarda C, Salemi VM, Morris M, De Angelis K, Irigoyen MC: Impact of aging on cardiac function in a female rat model of menopause: role of autonomic control, inflammation, and oxidative stress. *Clin Interv Aging* 2016;11:341-350.
- 6 Goldberg EL, Dixit VD: Drivers of age-related inflammation and strategies for healthspan extension. *Immunol Rev* 2015;265:63-74.
- 7 Salminen A, Kaarniranta K, Kauppinen A: Inflammaging: disturbed interplay between autophagy and inflammasomes. *Aging* 2012;4:166-175.
- 8 Si H, Liu D: Dietary antiaging phytochemicals and mechanisms associated with prolonged survival. *J Nutr Biochem* 2014;25:581-591.
- 9 Liu Y, Sun HL, Li DL, Wang LY, Gao Y, Wang YP, Du ZM, Lu YJ, Yang BF: Choline produces antiarrhythmic actions in animal models by cardiac M<sub>3</sub> receptors: improvement of intracellular Ca<sup>2+</sup> handling as a common mechanism. *Can J Physiol Pharmacol* 2008;86:860-865.

- 10 Wang S, Han HM, Jiang YN, Wang C, Song HX, Pan ZY, Fan K, Du J, Fan YH, Du ZM, Liu Y: Activation of cardiac M3 muscarinic acetylcholine receptors has cardioprotective effects against ischaemia-induced arrhythmias. *Clin Exp Pharmacol Physiol* 2012;39:343-349.
- 11 Liu Y, Du J, Gao Y, Zhang Y, Cai BZ, Zhao H, Qi HP, Du ZM, Lu YJ, Yang BF: Role of M3 receptor in aconitine/barium-chloride-induced preconditioning against arrhythmias in rats. *Naunyn Schmiedebergs Arch Pharmacol* 2009;379:511-515.
- 12 Shi H, Wang H, Yang B, Xu D, Wang Z: The M3 receptor-mediated K(+) current (IKM3), a G(q) protein-coupled K(+) channel. *J Biol Chem* 2004;279:21774-21778.
- 13 Shi H, Wang H, Li D, Nattel S, Wang Z: Differential alterations of receptor densities of three muscarinic acetylcholine receptor subtypes and current densities of the corresponding K+ channels in canine atria with atrial fibrillation induced by experimental congestive heart failure. *Cell Physiol Biochem* 2004;14:31-40.
- 14 Liu Y, Wang S, Wang C, Song H, Han H, Hang P, Jiang Y, Wei L, Huo R, Sun L, Gao X, Lu Y, Du Z: Upregulation of M(3) muscarinic receptor inhibits cardiac hypertrophy induced by angiotensin II. *J Transl Med* 2013;11:209.
- 15 Wang S, Han HM, Pan ZW, Hang PZ, Sun LH, Jiang YN, Song HX, Du ZM, Liu Y: Choline inhibits angiotensin II-induced cardiac hypertrophy by intracellular calcium signal and p38 MAPK pathway. *Naunyn Schmiedebergs Arch Pharmacol* 2012;385:823-831.
- 16 Jiang Y, Du W, Chu Q, Qin Y, Tuguzbaeva G, Wang H, Li A, Li G, Li Y, Chai L, Yue E, Sun X, Wang Z, Pavlov V, Yang B, Bai Y: Downregulation of Long Non-Coding RNA Kcnq1ot1: An important mechanism of arsenic trioxide-induced long QT syndrome. *Cell Physiol Biochem* 2018;45:192-202.
- 17 Zhao Q, Huang C, Jiang H, Okello E, Tang YH, Wang Z, Wu Z: M2 and M3-muscarinic acetylcholine receptors remodelling in patients with a dilated atrium. *Acta cardiol* 2008;63:166-170.
- 18 Volt H, Garcia JA, Doerrier C, Diaz-Casado ME, Guerra-Librero A, Lopez LC, Escames G, Tresguerres JA, Acuna-Castroviejo D: Same molecule but different expression: aging and sepsis trigger NLRP3 inflammasome activation, a target of melatonin. *J Pineal Res* 2016;60:193-205.
- 19 Cordero MD, Williams MR, Ryffel B: AMP-Activated Protein Kinase Regulation of the NLRP3 Inflammasome during Aging. *Trends Endocrinol Metab* 2018;29:8-17.
- 20 Huang Z, Zhuang X, Xie C, Hu X, Dong X, Guo Y, Li S, Liao X: Exogenous hydrogen sulfide attenuates high glucose-induced cardiotoxicity by inhibiting NLRP3 inflammasome activation by suppressing TLR4/NF-kappaB Pathway in H9c2 Cells. *Cell Physiol Biochem* 2016;40:1578-1590.
- 21 Li T, Li L, Li F, Liu Y: X-ray irradiation accelerates senescence in hippocampal neural stem/progenitor cells via caspase-1 activation. *Neurosci Lett* 2015;585:60-65.
- 22 Toldo S, Seropian IM, Mezzaroma E, Van Tassel BW, Salloum FN, Lewis EC, Voelkel N, Dinarello CA, Abbate A: Alpha-1 antitrypsin inhibits caspase-1 and protects from acute myocardial ischemia-reperfusion injury. *J Mol Cell Cardiol* 2011;51:244-251.
- 23 Hang P, Zhao J, Qi J, Wang Y, Wu J, Du Z: Novel insights into the pervasive role of M(3) muscarinic receptor in cardiac diseases. *Curr Drug Targets* 2013;14:372-377.
- 24 Xu ZP, Yang K, Xu GN, Zhu L, Hou LN, Zhang WH, Chen HZ, Cui YY: Role of M3 mAChR in *in vivo* and *in vitro* models of LPS-induced inflammatory response. *Int Immunopharmacol* 2012;14:320-327.
- 25 Espanol AJ, Maddaleno MO, Lombardi MG, Cella M, Martinez Pulido P, Sales ME: Treatment with LPS plus INF-gamma induces the expression and function of muscarinic acetylcholine receptors, modulating NIH3T3 cell proliferation: participation of NOS and COX. *Br J Pharmacol* 2014;171:5154-5167.